The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of veliparib (ABT-888) in combination with capecitabine (C) and temozolomide (T) in patients (pts) with advanced well-differentiated unresectable neuroendocrine tumors (wdNET).
 
Ramya Thota
No Relationships to Disclose
 
Kimberly Brown Dahlman
No Relationships to Disclose
 
Tatsuki Koyoma
No Relationships to Disclose
 
Jordan Berlin
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Genentech/Roche; ipsen; Lilly/ImClone; Novartis; Symphony Evolution; targovax; Vertex
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bayer/Onyx (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Merrimack (Inst); Novartis (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Otsuka (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Abbvie
Other Relationship - Incyte